Videos de Experimentos Relacionados
Resumen
La risa reduce significativamente la amplitud del reflejo H, lo que indica que la inhibición motora puede causar la sensación de "debilidad con la risa". Este hallazgo puede explicar la risa.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Fisiología Fisiología Fisiología.
Sus antecedentes:
- La risa es un comportamiento humano complejo con fundamentos fisiológicos poco conocidos.
- La experiencia subjetiva del sentimiento.
Videos de Conceptos Relacionados
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Efficacy, safety, and tolerability of low sodium oxybate for nocturnal cluster headache attacks in chronic cluster headache: protocol for a phase II randomized, double-blind, placebo-controlled, trial (SUNCET).
Pain management·2026
Same author
Corticotropin-Releasing Hormone (CRH) in Murine Narcolepsy: What Do Genetic and Immune Models Tell Us?
Journal of sleep research·2025
Same author
Deep clustering of polysomnography data to characterize sleep structure in healthy sleep and non-rapid eye movement parasomnias.
Journal of neuroscience methods·2025
Same author
Symptoms of central disorders of hypersomnolence during phases of female hormonal transitions: an explorative self-report study.
Sleep medicine·2025
Same author
Diagnostic and societal impact of implementing the syncope guidelines of the European Society of Cardiology (SYNERGY study).
BMC medicine·2023
Same author
Automated sleep staging in people with intellectual disabilities using heart rate and respiration variability.
Journal of intellectual disability research : JIDR·2023
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026